ALC

Alcon Inc. (ALC) | Rumor.io

Alcon

ALC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,524

Bullish sentiment (50-day avg)97%

Price to earnings ratio49.3

Market capitalization31.5B

Earnings per share1.31

Dividend yield (TTM)2.19%

Revenue (annual)10.4B

Net income (annual)980M

Social

What share of all stock conversation is about ALC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0.02% +0.02

May 5

Alcon Inc. (ALC) reported a 27% surge in Surgical Equipment sales, driven by the Unity platform rollout.
The top-line growth was driven by the success of Alcon's new product launches, including the Unity and Tryptyr platforms.
Alcon's Q1 2026 earnings were boosted by the supercycle in Unity Equipment, masking GAAP profitability noise.

Generated by AI

Sentiment

Of the messages about ALC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +5.45	87.25% -1.89
Bearish	—	0%	0% -5.45	12.75% +1.89

Topics

Of the messages about ALC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	16.46%
Earnings	—	—	0%	5.34%
Analysts	—	—	0%	0.7%
Controversies	—	—	0%	1.39%
Macro	—	—	0%	76.01%
Technical Analysis	—	—	0%	0.1%

Analysts· Aug 19

Alcon Inc. has received various analyst updates, with Wells Fargo maintaining an Overweight rating and raising the price target to $90.
Credit Suisse analyst Matt Miksic maintains an Outperform rating on Alcon, raising the price target from $86 to $90, while BTIG analyst Ryan Zimmerman maintains a Buy rating, raising the target from $80 to $84.
Morgan Stanley, SVB Leerink, and Credit Suisse have also updated their ratings on Alcon, maintaining Overweight, Market Perform, and Outperform ratings, respectively, with price target increases to $92, $82, and $90.

Announcements· Dec 9

Alcon has amended its merger agreement with STAAR Surgical, increasing the acquisition price to $30.75 per share from $28.
The revised offer adds $150M in equity value and values the deal at approximately $1.6B, with both boards supporting the amended merger.
The updated agreement aims to secure shareholder approval and is expected to close in early 2026, pending regulatory approvals.

Generated by AI

Community

Of the messages about ALC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	83.33%	55.88%	2.71%
Newcomers	100%	16.67%	44.12%	97.29%

Regulars· Nov 11

Alcon's Q3 2025 results show a 6.41% YoY revenue growth, but missed estimates by $5.4M, and a 166.67% YoY EPS growth, but missed estimates by $0.03.
The company's earnings beat on adjusted EPS, but revenue missed estimates, with a 2.66% decline in earnings compared to the same period last year.
Alcon's Unity VCS business is showing strong momentum, leading growth in the quarter with accelerated equipment sales.

Newcomers· Nov 12

Newcomers are focused on Alcon's Q3 results, with some beating expectations and others meeting them, with the company's guidance being a key point of discussion.
The analysts are discussing Alcon's strong momentum in sales, particularly in its Unity VCS, which is driving growth in the surgical sector, and the company's ability to maintain its core EPS and revenue guidance.
Investors are reassessing Alcon's valuation, with some seeing its 35x P/E ratio as stable, and others looking at its gross margin expansion and innovation in surgical tech and ocular health as key factors in its leadership position.

Generated by AI

Alcon has seen its share price grind lower in recent years, which naturally puts a spotlight on whether the current valuation still lines up with what the business earns. For anyone tracking the stock, the core question is whether the recent price level reflects a fair read of Alcon's earnings power. The share price has declined 26.8% over the past 5 years, which puts real pressure on the idea that the current market value is in step with the earnings the company produces. The business model...

3d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Intuitive Surgical (ISRG)

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

8d agoThe Globe and Mail

Alcon CEO Says US Drug Pricing Deal May Limit European Products

16d agoBloomberg.com

Mason Cisney Alcon Wealth Management Group Joins UBS in Pueblo, CO

PUEBLO, Colo., September 04, 2026--UBS today announced that Financial Advisors Caitlin Alcon, Calvin Mason, and Craig Cisney will be joining the firm. They will be joining the UBS Mountain West Market, managed by Mitch Markley, and will report to Market Director Justin French.

26d agoYahoo Finance

Also Discussed

Investors talking about ALC also mention

#	Name	Attention
1	STAAR Surgical CompanySTAA	0%new
2	Carlisle Cos IncCSL	0%new
3	Bausch + Lomb CorporationBLCO	0%0
4	SCU - Sculptor Capital Management, Inc.	——
5	CLI - Mack-Cali Realty Corporation	——
6	Nuveen New York Quality Municipal Income FundNAN	0%new
7	Vanguard Health Care ETFVHT	0.13%+0.12
8	Five Point Holdings LLC Class A Common SharesFPH	0%new
9	Optical Cable CorporationOCC	0%new
10	iShares MSCI Thailand ETFTHD	0%0

Alcon Inc.

Healthcare
Medical Instruments & Supplies

Alcon Inc. is a global eye care company focused on products and technologies that support vision health across surgical and everyday care settings. Alcon Inc. develops, manufactures, and markets a broad portfolio for cataract surgery, vitreoretinal procedures, glaucoma care, refractive surgery, contact lenses, lens care, and other ocular health needs. Its Surgical business provides implantable products, surgical equipment, diagnostics, and consumables used by ophthalmologists in hospitals and specialty clinics. Its Vision Care business includes daily disposable and reusable contact lenses, color-enhancing lenses, and a range of eye health products for dry eye, allergies, glaucoma support, contact lens care, and redness relief. Headquartered in Geneva, Switzerland, Alcon Inc. serves eye care professionals, medical institutions, and consumers in markets worldwide as a leading provider in ophthalmology and vision care.

Website

Location

Chemin de Blandonnet 8

Geneva, MI, 1214

Switzerland

Social

What share of all stock conversation is about ALC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0.02% +0.02

May 5

Alcon Inc. (ALC) reported a 27% surge in Surgical Equipment sales, driven by the Unity platform rollout.
The top-line growth was driven by the success of Alcon's new product launches, including the Unity and Tryptyr platforms.
Alcon's Q1 2026 earnings were boosted by the supercycle in Unity Equipment, masking GAAP profitability noise.

Generated by AI

Sentiment

Of the messages about ALC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +5.45	87.25% -1.89
Bearish	—	0%	0% -5.45	12.75% +1.89

Topics

Of the messages about ALC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	16.46%
Earnings	—	—	0%	5.34%
Analysts	—	—	0%	0.7%
Controversies	—	—	0%	1.39%
Macro	—	—	0%	76.01%
Technical Analysis	—	—	0%	0.1%

Analysts· Aug 19

Alcon Inc. has received various analyst updates, with Wells Fargo maintaining an Overweight rating and raising the price target to $90.
Credit Suisse analyst Matt Miksic maintains an Outperform rating on Alcon, raising the price target from $86 to $90, while BTIG analyst Ryan Zimmerman maintains a Buy rating, raising the target from $80 to $84.
Morgan Stanley, SVB Leerink, and Credit Suisse have also updated their ratings on Alcon, maintaining Overweight, Market Perform, and Outperform ratings, respectively, with price target increases to $92, $82, and $90.

Announcements· Dec 9

Alcon has amended its merger agreement with STAAR Surgical, increasing the acquisition price to $30.75 per share from $28.
The revised offer adds $150M in equity value and values the deal at approximately $1.6B, with both boards supporting the amended merger.
The updated agreement aims to secure shareholder approval and is expected to close in early 2026, pending regulatory approvals.

Generated by AI

Community

Of the messages about ALC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	83.33%	55.88%	2.71%
Newcomers	100%	16.67%	44.12%	97.29%

Regulars· Nov 11

Alcon's Q3 2025 results show a 6.41% YoY revenue growth, but missed estimates by $5.4M, and a 166.67% YoY EPS growth, but missed estimates by $0.03.
The company's earnings beat on adjusted EPS, but revenue missed estimates, with a 2.66% decline in earnings compared to the same period last year.
Alcon's Unity VCS business is showing strong momentum, leading growth in the quarter with accelerated equipment sales.

Newcomers· Nov 12

Newcomers are focused on Alcon's Q3 results, with some beating expectations and others meeting them, with the company's guidance being a key point of discussion.
The analysts are discussing Alcon's strong momentum in sales, particularly in its Unity VCS, which is driving growth in the surgical sector, and the company's ability to maintain its core EPS and revenue guidance.
Investors are reassessing Alcon's valuation, with some seeing its 35x P/E ratio as stable, and others looking at its gross margin expansion and innovation in surgical tech and ocular health as key factors in its leadership position.

Generated by AI

Alcon

Social

May 5

Sentiment

Topics

Analysts· Aug 19

Announcements· Dec 9

Community

Regulars· Nov 11

Newcomers· Nov 12

News

Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief

Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings Pressure

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)

Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Intuitive Surgical (ISRG)

Alcon CEO Says US Drug Pricing Deal May Limit European Products

Mason Cisney Alcon Wealth Management Group Joins UBS in Pueblo, CO

Also Discussed

Alcon Inc.

Company Information

Location

News

Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief

Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings Pressure

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Alcon (ALC)

Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Intuitive Surgical (ISRG)

Alcon CEO Says US Drug Pricing Deal May Limit European Products

Mason Cisney Alcon Wealth Management Group Joins UBS in Pueblo, CO

Also Discussed

Social

May 5

Sentiment

Topics

Analysts· Aug 19

Announcements· Dec 9

Community

Regulars· Nov 11

Newcomers· Nov 12